1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 22nd April 2024 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Nature: ‘It’s all gone’: CAR-T therapy forces autoimmune diseases into remission

Discussion in 'Other health news and research' started by rvallee, Dec 12, 2023.

  1. Pibee

    Pibee Established Member (Voting Rights)

    Messages:
    70
    Location:
    Europe_the healthcareless hell
    seems CD19 wont be enough for MS, ... at least based on OCB just dropping in 1 patient and persisting in other, that's discouraging. It might still work very very well better than whatever they have now (like CD20 monoclonals or HSCT), but I read and think these 2 case reports indicate you need to reset plasma cells as well to fully cure MS.

    and it's a bit weird report, unclear if they had RRMS or PPMS...
     
    EndME, Jaybee00 and Kitty like this.
  2. Jonathan Edwards

    Jonathan Edwards Senior Member (Voting Rights)

    Messages:
    13,577
    Location:
    London, UK
    Probably right but I would be careful about using oligoclonal bands as an endpoint in the shorter term (less than a year). The kinetics of response is likely to be very complex and in most patients the clinical aim is to prevent new demyelinating foci. Nobody knows what determine those but it may not relate to persistent antibody production the CNS compartment directly.

    It will be very interesting to see. I agree that more clinical detail would have been helpful.
     
    Eddie, FMMM1, MeSci and 4 others like this.
  3. EndME

    EndME Senior Member (Voting Rights)

    Messages:
    876
    The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases

    Summary
    Chimeric antigen receptor (CAR) T cells have made a groundbreaking advancement in personalized immunotherapy and achieved widespread success in hematological malignancies. As CAR technology continues to evolve, numerous studies have unveiled its potential far beyond the realm of oncology. This review focuses on the current applications of CAR-based cellular platforms in non-neoplastic indications, such as autoimmune, infectious, fibrotic, and cellular senescence-associated diseases. Furthermore, we delve into the utilization of CARs in non-T cell populations such as natural killer (NK) cells and macrophages, highlighting their therapeutic potential in non-neoplastic conditions and offering the potential for targeted, personalized therapies to improve patient outcomes and enhanced quality of life.

    https://www.cell.com/med/fulltext/S2666-6340(24)00128-4
     
    Kitty and Hutan like this.
  4. Jonathan Edwards

    Jonathan Edwards Senior Member (Voting Rights)

    Messages:
    13,577
    Location:
    London, UK
    A review from authors in Wuhan!!
    And published in something called 'Med'
    Is this AI??
     
    Hutan, Kitty, Eddie and 1 other person like this.
  5. Jaybee00

    Jaybee00 Senior Member (Voting Rights)

    Messages:
    1,906
    It’s an enchanting canvas!!!
     
    Hutan and Kitty like this.
  6. Jonathan Edwards

    Jonathan Edwards Senior Member (Voting Rights)

    Messages:
    13,577
    Location:
    London, UK
    Generally speaking you want a canvas to be evenly primed, either with rabbit size or some modern emulsion foundation, and to have some texture but no other features - certain not irregularities.

    Maybe the AI picked the wrong metaphor?
     
    Amw66 and FMMM1 like this.
  7. Jaybee00

    Jaybee00 Senior Member (Voting Rights)

    Messages:
    1,906

Share This Page